Centessa Pharmaceuticals PLC ADR (CNTA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Centessa Pharmaceuticals PLC ADR stock (CNTA) is currently trading at $27.89. Centessa Pharmaceuticals PLC ADR PS ratio (Price-to-Sales) is 263.52. Analyst consensus price target for CNTA is $40.38. WallStSmart rates CNTA as Sell.
- CNTA PE ratio analysis and historical PE chart
- CNTA PS ratio (Price-to-Sales) history and trend
- CNTA intrinsic value — DCF, Graham Number, EPV models
- CNTA stock price prediction 2025 2026 2027 2028 2029 2030
- CNTA fair value vs current price
- CNTA insider transactions and insider buying
- Is CNTA undervalued or overvalued?
- Centessa Pharmaceuticals PLC ADR financial analysis — revenue, earnings, cash flow
- CNTA Piotroski F-Score and Altman Z-Score
- CNTA analyst price target and Smart Rating
Centessa Pharmaceuticals PLC ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Centessa Pharmaceuticals PLC ADR (CNTA) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Centessa Pharmaceuticals PLC ADR (CNTA) Key Strengths (2)
101.82% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Centessa Pharmaceuticals PLC ADR (CNTA) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very expensive at 263.5x annual revenue
Very expensive at 13.3x book value
Supporting Valuation Data
Centessa Pharmaceuticals PLC ADR (CNTA) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 8.5/10) while 4 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (263.52), Price/Book (13.26) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -60.60%, Operating Margin at -1425.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -60.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CNTA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CNTA's Price-to-Sales ratio of 263.52x trades 20% below its historical average of 329.46x (34th percentile). The current valuation is 57% below its historical high of 618.79x set in Nov 2025, and 52% above its historical low of 172.87x in Jan 2024. Over the past 12 months, the PS ratio has compressed from ~311.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Centessa Pharmaceuticals PLC ADR (CNTA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Centessa Pharmaceuticals PLC ADR operates as a stable business with moderate growth and solid fundamentals. Revenue reached 15M with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 277% of revenue (42M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -59M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.55, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Centessa Pharmaceuticals PLC ADR.
Bottom Line
Centessa Pharmaceuticals PLC ADR offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Centessa Pharmaceuticals PLC ADR(CNTA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers drugs that change and improve the lives of patients. The company is headquartered in Cambridge, the United Kingdom.